Crohn’s Disease (Regional Enteritis) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) – Pipeline Review, H1 2020’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)

– The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects

– The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AbbVie Inc

Abivax SA

Aclaris Therapeutics Inc

Active Biotech AB

Affilogic SAS

Aibios Co Ltd

Akeso Biopharma Inc

AlfaSigma SpA

Algernon Pharmaceuticals Inc

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech ehf

Amgen Inc

Anterogen Co Ltd

Antibe Therapeutics Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Artizan Biosciences Inc

Asdera LLC

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Avexegen Therapeutics Inc

Avobis Bio

Axim Biotechnologies Inc

Baylx Inc

BioLingus AG

Biond Biologics Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Celltrion Inc

Celularity Inc

ChemoCentryx Inc

Chong Kun Dang Pharmaceutical Corp

Commence Bio Inc

Cytocom Inc

Daiichi Sankyo Co Ltd

DBV Technologies SA

Defensin Therapeutics ApS

Denali Therapeutics Inc

DM Bio Ltd

DNX Biopharmaceuticals Inc

EA Pharma Co Ltd

Eisai Co Ltd

Eli Lilly and Co

Enterome Bioscience SA

Enzo Biochem Inc

ETX Pharma Inc

ExCellThera Inc

Exeliom Biosciences SAS

Ferring International Center SA

Fimbrion Therapeutics Inc

Finch Therapeutics Group

Fujifilm Kyowa Kirin Biologics Co Ltd

FYB202 GmbH & Co KG

Galactica Biotech Ltd

Galapagos NV

Genentech Inc

GlaxoSmithKline Plc

Gossamer Bio Inc

HAV Vaccines Ltd

Immunic Inc

Inception Sciences Inc

InDex Pharmaceuticals Holding AB

InflammatoRx inc

Innovate Biopharmaceuticals Inc

Innovation Pharmaceuticals Inc

Innovent Biologics Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Inspyr Therapeutics Inc

Intract Pharma Ltd

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jyant Technologies Inc

Kang Stem Biotech Co Ltd

Koutif Therapeutics LLC

Kyowa Kirin Co Ltd

Landos Biopharma Inc

Locus Biosciences Inc

Machavert Pharmaceuticals LLC

Macrophage Therapeutics Inc

MAKScientific LLC

Menemsha Pharmaceuticals Ltd

Mesoblast Ltd

Metacrine Inc

MetiMedi Pharmaceuticals Co Ltd

MGC Pharmaceuticals Ltd

Mitsubishi Tanabe Pharma Corp

Morphic Holding Inc

Mycenax Biotech Inc

Naia Rare Diseases Inc

NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd

Nimbus Therapeutics LLC

Oncodesign SA

OSE Immunotherapeutics

Otsuka Holdings Co Ltd

PanTheryx Inc

Par'Immune SAS

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Pharmapraxis

Polpharma Biologics

Praeventix LLC

Protagonist Therapeutics Inc

Protheragen Inc

Qu Biologics Inc

Re-Pharm Ltd

Rebiotix Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Regentys Corp

Reponex Pharmaceuticals Aps

Saje Pharma LLC

Saniona AB

Semorex Technologies Ltd

Seres Therapeutics Inc

Siam Bioscience Co Ltd

Soligenix Inc

STERO Biotechs Ltd

Suzhou Connect Biopharmaceuticals Ltd

Synedgen Inc

Synlogic Inc

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Temisis Therapeutics

Tetherex Pharmaceuticals Corp

The Cell Factory BVBA

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tiziana Life Sciences Plc

TRACT Therapeutics Inc

Trio Medicines Ltd

Ventria Bioscience

VHsquared Ltd

Winston Pharmaceuticals Inc

XBiotech Inc

Xbrane Biopharma AB

Yom Chai

Table of Contents

Table of Contents

Introduction

Crohn's Disease (Regional Enteritis) – Overview

Crohn's Disease (Regional Enteritis) – Therapeutics Development

Crohn's Disease (Regional Enteritis) – Therapeutics Assessment

Crohn's Disease (Regional Enteritis) – Companies Involved in Therapeutics Development

Crohn's Disease (Regional Enteritis) – Drug Profiles

Crohn's Disease (Regional Enteritis) – Dormant Projects

Crohn's Disease (Regional Enteritis) – Discontinued Products

Crohn's Disease (Regional Enteritis) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Companies, H1 2020 (Contd..10), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Crohn's Disease (Regional Enteritis) – Pipeline by 4D Pharma Plc, H1 2020

Crohn's Disease (Regional Enteritis) – Pipeline by AbbVie Inc, H1 2020

Crohn's Disease (Regional Enteritis) – Pipeline by Abivax SA, H1 2020

Crohn's Disease (Regional Enteritis) – Pipeline by Aclaris Therapeutics Inc, H1 2020

Crohn's Disease (Regional Enteritis) – Pipeline by Active Biotech AB, H1 2020

Crohn's Disease (Regional Enteritis) – Dormant Projects, H1 2020

Crohn's Disease (Regional Enteritis) – Discontinued Products, H1 2020

Crohn's Disease (Regional Enteritis) – Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports